Table 2.
Clinical manifestations at the last follow-up in AO, RO, and MO subgroups
| Auricular involvement, n, (% of the group)a | Respiratory involvement, n, (%)b | Ocular involvement, n, (%)c | Nasal involvement, n, (%) | Joint involvement, n, (%) | Inner ear involvement, n, (%)c | Skin involvement, n, (%) | CNS involvement, n, (%)d | Renal involvement, n, (%) | Cardiovascular involvement, n, (%)d | |
|---|---|---|---|---|---|---|---|---|---|---|
| All 229 patients | 182, (79%) | 112, (49%) | 113, (49%) | 91, (40%) | 90, (39%) | 64, (30%) | 32, (14%) | 28, (12%) | 18, (7.9%) | 16, (7.0%) |
| AO, 135 patients | 135, (100%) | 44, (33%) | 60, (44%) | 49, (36%) | 60, (44%) | 32, (24%) | 19, (14%) | 17, (13%) | 10, (7.4%) | 10, (7.4%) |
| RO, 48 patients | 9, (19%) | 48, (100%) | 17, (35%) | 25, (52%) | 13, (27%) | 8, (17%) | 5, (10%) | 1, (2.1%) | 2, (4.2%) | 0, (0.0%) |
| MO, 46 patients | 38, (83%) | 20, (43%) | 34, (74%) | 15, (33%) | 16, (35%) | 24, (52%) | 8, (17%) | 10, (21%) | 6, (13%) | 6, (13%) |
aThe incidence was significantly higher in AO patients than that in RO patients and that in MO patients. The incidence was significantly higher in MO patients than that in RO patients
bThe incidence was significantly higher in RO patients than that in AO patients and that in MO patients
cThe incidence was significantly higher in MO patients than that in AO patients and that in RO patients
dThe incidence was significantly higher in MO patients than that in RO patients